Moll Wendén has advised Qlife Holding AB in connection with a rights issue of shares raising approximately SEK 26.0 million.
Qlife is a med-tech group that strives to revolutionize the market for clinical biomarker and virus tests. By enabling tests at home through the company’s Egoo.Health Platform as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases. Qlife is listed on Nasdaq First North Growth Market.
Qlife has carried out a rights issue of shares whereby Qlife will receive approximately SEK 26.0 million before issue costs and set-off. The proceeds from the rights issue will be used to finance commercial partnerships, sales and regulatory proceedings in the EU and United Kingdom as well as general corporate purposes.